• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Karen Flynn to Board of Directors

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTLT alert in real time by email

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

    Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer health products. Prior to this, she held the positions of Chief Commercial Officer and President of Biologics at Catalent. Prior to Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services (NYSE:WST), and as President of its Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation and quality management.

    "We are excited to welcome Karen to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Karen's extensive commercial expertise in pharmaceutical services will serve as a tremendous asset as we continue to grow. Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company."

    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (NASDAQ:QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent. She has also served on the Board of Recro Pharma, Inc., a specialty pharma and contract development and manufacturing organization, where she was Chair of the Compensation Committee and a member of the Audit Committee.

    Ms. Flynn holds a Master of Science in Engineering from University of Pennsylvania and a Master of Science in Business Administration from Boston University. She completed her Bachelor of Science at the University of Notre Dame.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts

    Jason Peterson

    Vice President & Treasurer, Sotera Health

    [email protected]

    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $CTLT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTLT
    $QTRX
    $SHC
    $WST

    CompanyDatePrice TargetRatingAnalyst
    West Pharmaceutical Services Inc.
    $WST
    6/24/2025$245.00Equal Weight
    Barclays
    Sotera Health Company
    $SHC
    5/5/2025$17.00Neutral → Buy
    Goldman
    West Pharmaceutical Services Inc.
    $WST
    3/18/2025$275.00Outperform
    Evercore ISI
    West Pharmaceutical Services Inc.
    $WST
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    West Pharmaceutical Services Inc.
    $WST
    1/8/2025$400.00Buy
    Citigroup
    West Pharmaceutical Services Inc.
    $WST
    12/13/2024Peer Perform
    Wolfe Research
    West Pharmaceutical Services Inc.
    $WST
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    Sotera Health Company
    $SHC
    12/6/2024$14.00Neutral
    Goldman
    More analyst ratings

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lai Goldman Myla was granted 27,404 shares (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      7/10/25 8:39:39 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Mendel Scott was granted 28,653 shares (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      7/10/25 8:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Lai Goldman Myla

      3 - Quanterix Corp (0001503274) (Issuer)

      7/9/25 9:14:02 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ("RSUs") representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the o

      7/11/25 5:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

      Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said

      7/8/25 9:07:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West to Host Second-Quarter 2025 Conference Call

      EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participa

      7/8/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Quanterix Corporation

      S-8 POS - Quanterix Corp (0001503274) (Filer)

      7/11/25 5:04:03 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by Quanterix Corporation

      S-8 - Quanterix Corp (0001503274) (Filer)

      7/11/25 5:03:50 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Quanterix Corp (0001503274) (Filer)

      7/8/25 9:14:39 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on West Pharm with a new price target

      Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

      6/24/25 8:11:45 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

      Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said

      7/8/25 9:07:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Catalent Announces New Board Appointments

      Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

      2/20/25 9:00:00 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Financials

    Live finance-specific insights

    See more
    • West to Host Second-Quarter 2025 Conference Call

      EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participa

      7/8/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalent Inc.

      SC 13G/A - Catalent, Inc. (0001596783) (Subject)

      11/14/24 4:35:03 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care